|4Mar 28, 4:08 PM ET

Happel David 4

4 · Sagimet Biosciences Inc. · Filed Mar 28, 2024

Insider Transaction Report

Form 4
Period: 2024-03-26
Happel David
DirectorPresident & CEO
Transactions
  • Purchase

    Series A Common Stock

    2024-03-26$5.27/sh+12,100$63,731639,200 total
Footnotes (1)
  • [F1]Reflects the weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.24 per share to $5.2999 per share. The Reporting Person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each price.

Documents

1 file
  • 4
    tm2410115-1_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT